The dangers of counterfeit and substandard active pharmaceutical ingredients

WHO Drug Information

Volumn 11, Issue 3, 1997, Pages 123-127

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLENE GLYCOL; ORPHAN DRUG; OXYTETRACYCLINE; SULFAMETHOXAZOLE;

AUSTRALIA; DRUG CONTAMINATION; DRUG CONTROL; DRUG INDUSTRY; DRUG LABELING; DRUG LEGISLATION; DRUG SAFETY; DRUG USE; LICENSING; REVIEW; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 0030808783     PISSN: 10109609     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. World Health Assembly resolution WHA 41.16.
2. World Health Organization. Counterfeit drugs: report of a joint WHO/IFPMA workshop. WHO/DMP/CFD/92, WHO, Geneva 1992.
3. WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-second Report. WHO Technical Report Series, Number 823, WHO, Geneva, 1992.
4. Note from the Therapeutics Goods Administration (TGA) entitled Substitution of Active Pharmaceutical Ingredients, distributed during PIC-PIC/S meeting of officials in Geneva in February 1997. Communication from the TGA addressed to WHO dated 3 and 25 March 1997.
5. Letters from the US FDA Office of Criminal Investigations addressed to WHO dated 28 February and 7 April 1997.
6. Letter from Medicines Control Agency, United Kingdom to WHO dated 2 June 1997.
7. Pan American Health Organization. Deaths in Haiti renal failure epidemic. PAHO News Release, 7 August 1996.